Chronic Kidney Disease Market Market Trends

Growth Drivers

• Increasing prevalence of diabetes and hypertension: The increase in the prevalence of diabetes and hypertension, being the already established causes of chronic kidney disease, strongly influences the chronic kidney disease market dynamics for CKD. As more people pick up these chronic ailments, the risk of acquiring CKD also goes upward, thereby opening ways for treatments that could work effectively. In July 2021, Bayer received US FDA approval for KEREND.
• Advancements in diagnostic technologies: Assistance regarding diagnosis with the availability of eGFR and imaging tests for new diagnostic technologies significantly supports early therapies, which delays disease development. For example, DaVita Kidney Care collaborated with Verily in August 2023 to develop digital health tools that would help improve chronic kidney disease care access. This ascertains true diagnostic tools that are timely and accessible, thus proving a driver in the growth of the chronic kidney disease market.
• Increasing awareness for the risk factors of CKD: Increasing awareness of the risk factors for chronic kidney disease has, in turn, bolstered demand for preventive care and early diagnostics of the disease. Public health campaigns increase awareness among the at-risk population and make them aware of check-up schedules. For instance, in August 2023, Novartis launched a global effort in an attempt to build awareness about chronic kidney disease and improve access to care. The example shows the industry's commitment to the prevention and management of CKD. This has been one of the growth factors for this chronic kidney disease market, as it increases the focus on preventive care.

Challenges

• Gaps in healthcare accessibility to CKD treatment: Inaccessibility of healthcare in poor-income regions is one of the major hindrances to the proper diagnosis and treatment of CKD. The absence of infrastructural facilities in regard to chronic kidney disease management prevents diagnostic and therapeutic essentialities from becoming available in these very regions. Distance and costs to higher healthcare facilities translate to delayed diagnosis and treatment for many patients, constraining better health outcomes. Besides, advanced diagnostics and therapies are highly restricted in their availability owing to high costs. Therefore, there is a greater need for affordable and scalable solutions tailored according to the requirements of underserved populations.
• Regulatory and approval barriers to new therapies: Stringent new therapy regulatory processes in CKD could further delay market entry and poor access for patients to new and innovative treatments. The resource- and time-consuming nature of overcoming these kinds of regulatory hurdles can often be prohibitive for smaller pharmaceutical companies. In addition, the different regulatory requirements across different regions contribute further to this complexity, with a possible consequence of poor global accessibility of newer and more effective chronic kidney disease therapies.